Annexon To Highlight Phase 3 ARCHER II Clinical Trial Program At Virtual Investor Event
Benzinga Newsdesk 3 weeks ago
BiotechGeneralEventsNews
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
Company management will highlight the Phase 3 ARCHER II clinical trial design, patient demographics and communication strategy for the anticipated 15-month and 24-month results beginning in Q4 2026. The Company will also highlight the recent strengthening of its Ophthalmology team.
